HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

balsalazide (Colazal)

a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source
Also Known As:
Colazal; 5-(carboxyethylcarbamoyl-4-phenylazo)salicylic acid; BX 661A; BX661A; Colazide; Salix brand of balsalazide disodium; Shire brand of balsalazide disodium; balsalazide disodium; balsalazine; Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt
Networked: 69 relevant articles (23 outcomes, 17 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Tursi, Antonio: 4 articles (12/2009 - 11/2004)
2. Johnson, Lorin K: 4 articles (11/2009 - 06/2002)
3. Pruitt, Ronald: 3 articles (06/2009 - 06/2002)
4. Thornton, P C: 3 articles (02/2004 - 01/2002)
5. Forbes, William P: 2 articles (11/2009 - 06/2009)
6. Mei, Qiao: 2 articles (07/2009 - 03/2009)
7. Hu, Jing: 2 articles (07/2009 - 03/2009)
8. Rahimi, Roja: 2 articles (06/2009 - 04/2009)
9. Abdollahi, Mohammad: 2 articles (06/2009 - 04/2009)
10. Nikfar, Shekoufeh: 2 articles (06/2009 - 04/2009)

Related Diseases

1. Ulcerative Colitis
2. Hemorrhage
06/01/2009 - "A significantly larger proportion of patients achieved clinical improvement and improvement in rectal bleeding in the balsalazide group vs. the placebo group (55 vs. 40%, P=0.02). "
06/01/2002 - "Eight weeks of treatment with 6.75 g of balsalazide daily provided significantly greater improvement than did balsalazide (2.25 g daily) in rectal bleeding (64.7% [6.75-g balsalazide] vs 32.4% [2.25-g balsalazide], p < 0.006), stool frequency (58.8% vs 29.4%, p < 0.006), sigmoidoscopic score (78.9% vs 52.5%, p < 0.015), and Physician's Global Assessment (73.7% vs 51.3%, p < 0.03). "
01/01/2014 - "The clinical response in the adult Colazal trials was defined as a reduction of rectal bleeding and improvement in at least one of the other assessed symptoms (stool frequency, patient functional assessment, abdominal pain, sigmoidoscopic grade, and physician's global assessment) assessed by the Sutherland UC Activity Index. "
06/01/2009 - "In a double-blind, multicenter study patients with symptoms of acute UC and a baseline Modified Mayo Disease Activity Index (MMDAI) score between 6 and 10, inclusive, with a subscale rating of > or =2 for both rectal bleeding and mucosal appearance were randomized to receive 3.3 g of balsalazide or placebo tablets twice daily for 8 weeks. "
12/01/2002 - "Significantly more balsalazide patients showed sigmoidoscopic (p = 0.002), stool frequency (p = 0.006), rectal bleeding (p = 0.006), and physician's global assessment score (p = 0.013) improvement by 14 days than did mesalamine patients. "
3. Diverticulitis
4. Abdominal Pain (Pain, Abdominal)
5. Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

Related Drugs and Biologics

1. Mesalamine (Mesalazine)
2. Sulfasalazine (Azulfidine)
3. olsalazine (Dipentum)
4. Tablets
5. Salicylic Acid (2 Hydroxybenzoic Acid)
6. Prebiotics
7. 6-Mercaptopurine (Mercaptopurine)
8. Oxidoreductases
9. Azathioprine (Imuran)
10. Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1. Chemoprevention
2. Radiotherapy